Page last updated: 2024-12-04

ureidosuccinic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ureidosuccinic acid, also known as carbamoylsuccinic acid, is a key intermediate in the biosynthesis of pyrimidines. It is formed by the condensation of carbamoyl phosphate and aspartate, catalyzed by the enzyme aspartate transcarbamoylase. This reaction is the first committed step in pyrimidine biosynthesis. Ureidosuccinic acid is a colorless, crystalline solid. It is a crucial component of the pyrimidine pathway and is highly studied for its potential role in controlling pyrimidine metabolism and its implications in various diseases. For example, it has been suggested that ureidosuccinic acid may play a role in the pathogenesis of cancer and autoimmune diseases. Research efforts are aimed at understanding its precise role in these conditions, its potential as a therapeutic target, and the development of novel drugs that target its synthesis or degradation.'

ureidosuccinic acid: RN given refers to (DL)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N-carbamoylaspartic acid : An N-carbamoylamino acid that is aspartic acid with one of its amino hydrogens replaced by a carbamoyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID279
CHEMBL ID1161506
CHEBI ID64850
SCHEMBL ID163119
SCHEMBL ID22718870
MeSH IDM0049719

Synonyms (56)

Synonym
EN300-30856
nsc120033
923-37-5
dl-aspartic acid, n-(aminocarbonyl)-
nsc-120033
succinic acid, ureido-
nsc14983 ,
2-ureidobutanedioic acid
n-carbamoylaspartic acid
carbamylaspartic acid
aspartic acid, n-carbamoyl-
ureidosuccinic acid
n-(aminocarbonyl)aspartic acid
NCI60_001036
aspartic acid, n-(aminocarbonyl)-
n-carbamyl-dl-aspartic acid
carbamoyl-l-aspartate
BMSE000453
n-(aminocarbonyl)-dl-aspartic acid
n-carbamoyl-dl-aspartic acid
carbamyl-dl-aspartic acid
chebi:64850 ,
CHEMBL1161506
2-(carbamoylamino)butanedioic acid
STK803147
AKOS003271980
BBL003547
o3y2ky16l1 ,
unii-o3y2ky16l1
nsc 120033
einecs 213-096-6
2-ureidosuccinic acid
dl-2-ureidobutanedioic acid
n-carbamoylaspartic acid, dl-
SCHEMBL163119
AKOS016844368
carbamoyl-dl-aspartic acid
HLKXYZVTANABHZ-UHFFFAOYSA-N
n-(aminocarbonyl)aspartic acid #
mfcd00042822
ureidosuccinic acid, 98.0-102.0% (t)
2-isoureidosuccinic acid
n-carbamoylaspartate
Q2823324
dl-n-carbamoylaspartic acid
AMY4428
CS-0099507
HY-128425
n-?carbamoyl-?dl-?aspartic acid
D89188
A915744
AS-57486
S6259
SCHEMBL22718870
n-arbamoyl-l-spartic acid
DTXSID701030182

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
N-carbamoyl-amino acid
aspartic acid derivativeAn amino acid derivative resulting from reaction of aspartic acid at the amino group or either of the carboxy groups, or from the replacement of any hydrogen of aspartic acid by a heteroatom. The definition normally excludes peptides containing aspartic acid residues.
C4-dicarboxylic acidAny dicarboxylic acid that contains four carbon atoms.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
De novo biosynthesis of pyrimidine ribonucleotides09

Protein Targets (1)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (21)

Processvia Protein(s)Taxonomy
liver developmentCAD proteinHomo sapiens (human)
'de novo' pyrimidine nucleobase biosynthetic processCAD proteinHomo sapiens (human)
UDP biosynthetic processCAD proteinHomo sapiens (human)
glutamine metabolic processCAD proteinHomo sapiens (human)
xenobiotic metabolic processCAD proteinHomo sapiens (human)
heart developmentCAD proteinHomo sapiens (human)
female pregnancyCAD proteinHomo sapiens (human)
lactationCAD proteinHomo sapiens (human)
response to amineCAD proteinHomo sapiens (human)
peptidyl-threonine phosphorylationCAD proteinHomo sapiens (human)
response to caffeineCAD proteinHomo sapiens (human)
animal organ regenerationCAD proteinHomo sapiens (human)
response to insulinCAD proteinHomo sapiens (human)
response to testosteroneCAD proteinHomo sapiens (human)
response to starvationCAD proteinHomo sapiens (human)
'de novo' UMP biosynthetic processCAD proteinHomo sapiens (human)
protein autophosphorylationCAD proteinHomo sapiens (human)
response to cortisolCAD proteinHomo sapiens (human)
cellular response to epidermal growth factor stimulusCAD proteinHomo sapiens (human)
citrulline biosynthetic processCAD proteinHomo sapiens (human)
UTP biosynthetic processCAD proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
aspartate carbamoyltransferase activityCAD proteinHomo sapiens (human)
carbamoyl-phosphate synthase (ammonia) activityCAD proteinHomo sapiens (human)
carbamoyl-phosphate synthase (glutamine-hydrolyzing) activityCAD proteinHomo sapiens (human)
dihydroorotase activityCAD proteinHomo sapiens (human)
glutaminase activityCAD proteinHomo sapiens (human)
protein kinase activityCAD proteinHomo sapiens (human)
protein bindingCAD proteinHomo sapiens (human)
ATP bindingCAD proteinHomo sapiens (human)
zinc ion bindingCAD proteinHomo sapiens (human)
enzyme bindingCAD proteinHomo sapiens (human)
identical protein bindingCAD proteinHomo sapiens (human)
aspartate bindingCAD proteinHomo sapiens (human)
carbamoyl-phosphate synthase (glutamine-hydrolyzing) activityCAD proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
nucleusCAD proteinHomo sapiens (human)
cytosolCAD proteinHomo sapiens (human)
membraneCAD proteinHomo sapiens (human)
nuclear matrixCAD proteinHomo sapiens (human)
cell projectionCAD proteinHomo sapiens (human)
neuronal cell bodyCAD proteinHomo sapiens (human)
terminal boutonCAD proteinHomo sapiens (human)
extracellular exosomeCAD proteinHomo sapiens (human)
protein-containing complexCAD proteinHomo sapiens (human)
cytoplasmCAD proteinHomo sapiens (human)
cytosolCAD proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1224817Assays to identify small molecules inhibitory for eIF4E expression2015Chemistry & biology, Jul-23, Volume: 22, Issue:7
Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds.
AID55735Kinetic constant for the inactivation of Dihydroorotase (DHO) at pH 6.01990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Analogues of carbamyl aspartate as inhibitors of dihydroorotase: preparation of boronic acid transition-state analogues and a zinc chelator carbamylhomocysteine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (51)

TimeframeStudies, This Drug (%)All Drugs %
pre-199028 (54.90)18.7374
1990's11 (21.57)18.2507
2000's6 (11.76)29.6817
2010's5 (9.80)24.3611
2020's1 (1.96)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.03

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.03 (24.57)
Research Supply Index3.95 (2.92)
Research Growth Index4.34 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.03)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.96%)6.00%
Case Studies1 (1.96%)4.05%
Observational0 (0.00%)0.25%
Other49 (96.08%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]